Interní Med. 2001; 3(5): 233-234

PTSMA v léčbě hypertrofické obstrukční kardiomyopatie - naše první zkušenosti

MUDr. Jan Krejčí, prof. MUDr. Jaroslav Meluzín CSc, MUDr. Ladislav Groch, prof. MUDr. Jiří Toman CSc, MUDr. Lenka Špinarová Ph.D, MUDr. Petr Hude, MUDr. Jan Sitar
I. interní kardioangiologická klinika FN u sv. Anny v Brně

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krejčí J, Meluzín J, Groch L, Toman J, Špinarová L, Hude P, Sitar J. PTSMA v léčbě hypertrofické obstrukční kardiomyopatie - naše první zkušenosti. Interní Med. 2001;3(5):233-234.

Úvod

V druhé polovině 90. let se objevila nová terapeutická metoda redukce gradientu mezi hrotem levé komory (LK) a výtokovým traktem LK (LVOT) u pacientů s hypertrofickou obstrukční kardiomyopatií. Jedná se o perkutánní transluminální septální myokardiální ablaci (PTSMA) neboli alkoholovou ablaci septa...

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. W.Ruzyllo, L.Chojnowska, M.Demkow et al.: Left ventricular outflouw tract decrease with non-surgical myocardial reduction improves exercise capacity in pacients with hypertrofic obstructive cardiomyopathy, European Heart Journal, 2000, 21, str. 770-777. Go to original source... Go to PubMed...
    2. J.Januška, J.Veselka, D.Tesař et al.: První zkušenosti s perkutánní transluminální septální myokardiální ablací, Cor et Vasa 1998, 40 (6) str. 302-303.
    3. L.Faber, H.Seggewiss, U.Gleichmann: Percutaneous Transluminal Septal Myocardial Ablation in Hypertrofic Obstructive Cardiomyopathy, Circulation 1998, str.2415-2422. Go to original source... Go to PubMed...
    4. P.Spirito, Ch.E.Seidman, W.J.McKenna et al.: The Management of Hypertrofic Cardiomyopathy, The New England Journal of Medicine, Mar. 13, 1997, 336 (11), str. 775-785. Go to original source... Go to PubMed...
    5. H.Seggewiss, U.Gleichmann, L.Faber et al.: Percutaneous Transluminal Septal Myocardial Ablation in Hypertrofic Obstructive Cardiomyopathy: Acute Results and 3-Month Follow-up in 25 Patients, J. Am. Coll. Cardiol. 1998, 31, str. 252-8. Go to original source... Go to PubMed...
    6. H.Seggewiss, L.Faber, U.Gleichmann et al.: Mid-term follow-up results after catheter treatment in hypertrofic obstructive cardiomyopathy, XIXth Congress of European Society of Cardiology, August 24-28, 1997, Stockholm, Sweden.
    7. P. Gregor: Hypertrofická kardiomyopatie, Scientia Medica 1992.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.